MET and pancreatic neuroendocrine tumor: Preclinical evidence clarified that the dual blockade of MET and VEGF signaling in RIP-Tag2 mice may reduce the invasive and metastatic capabilities of pancreatic NETs (paNET) cells with a synergistic effect, thereby providing a strong rationale for using CAB in this setting (Sennino et al. 2012).